U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: Eliglustat (Cerdelga): (Sanofi Genzyme): Indication: Gaucher Disease Type 1 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Aug.

Cover of Pharmacoeconomic Review Report: Eliglustat (Cerdelga)

Pharmacoeconomic Review Report: Eliglustat (Cerdelga): (Sanofi Genzyme): Indication: Gaucher Disease Type 1 [Internet].

Show details

Table 12CDR Cost Comparison Table for Drug Therapies for GD1

Drug/ComparatorStrengthDosage FormPrice ($)Recommended DoseAverage Daily Cost ($)Average Annual Drug Cost ($)
Eliglustat (Cerdelga)84 mgcapsule695.0000a84 mg once daily for PM patients

84 mg twice daily for IM or EM patients
PM: 695.00

IM/EM: 1.390.00
PM: 253,675

IM/EM: 507,350
ERTsb
Imiglucerase (Cerezyme)400 U/vialIV2,460.0000c60 U/kg q.2.w. (initial dosage range: 2.5 U/kg 3 times a week to 60 U/kg q.2.w.)1,054.29 to 1,932.86384,814 to 705,493
Taliglucerase alfa (Elelyso)200 U/vialIV648.3600d60 U/kg q.2.w. (initial dosage range: 30 U/kg q.2.w. to 60 U/kg q.2.w.)509.43 to 972.54185,940 to 354,977
Velaglucerase alfa (VPRIV)400 U/vialIV1,955.0000e60 U/kg q.2.w. (range: 15 U/kg q.2.w.to 60 U/kg q.2.w.)418.93 to 1,536.07152,909 to 560,666

AQPP = Association quèbèecoise des pharmaciens propriétaires; CDR = CADTH Common Drug Review; EM = CYP2D6 extensive metabolizer; ERT = enzyme replacement therapy; GD1 = Gaucher disease type 1; IM = CYP2D6 intermediate metabolizer; IV = intravenous; PM = CYP2D6 poor metabolizer; q.2.w. = every other week.

Note: Costs are based on a patient weight of 70 kg and include wastage of excess medication. Costs do not include administration or dispensing fees. A year is assumed to be 365 days, or 26.07 14-day periods.

a

Manufacturer’s submitted price.2

b

Although the recommended doses may differ in range, feedback from the clinical expert consulted for this review indicated that if a patient is switched between ERTs, they will remain at the same dose between treatments before being titrated to the lowest effective dose, if possible.

c

The AQPP price as reported by Quintiles IMS DeltaPA (March 2017).24 This is also the price used in CDR’s VPRIV recommendation report25 and confirmed by Sanofi, the manufacturer of both Cerezyme and Cerdelga.2

d

The wholesale list price, as reported by Quintiles IMS Delta PA (March 2017).24

e

Ontario Drug Benefit Program’s Exceptional Access Program list price (March 2017).

From: Appendix 1, Cost Comparison

Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Views

  • Cite this Page
  • PDF version of this title (960K)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...